A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma
Abstract
Leptomeningeal disease (LMD) occurs as a late complication of several human cancers and has no rationally designed treatment options. A major barrier to developing effective therapies for LMD is the lack of cell-based or preclinical models that recapitulate human disease. Here, we describe the development of in vitro and in vivo cultures of patient-derived cerebrospinal fluid circulating tumor cells (PD-CSF-CTCs) from patients with melanoma as a preclinical model to identify exploitable vulnerabilities in melanoma LMD.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 25, 2022
- Source ID
- 10.1093/neuonc/noac054
Entities
People
- Ann Chen
- Arnold B. Etame
- Brian J. Czerniecki
- Brittany R Evernden
- Derek Duckett
- Francesca Vena
- Gisela Caceres
- Inna Smalley
- James K C Liu
- John Puskas
- Joseph Johnson
- Keiran S M Smalley
- Michael Vogelbaum
- Nam Tran
- Paulo C Rodriguez
- Peter A. Forsyth
- Robert Macaulay
- Simon Bayle
- Vincent Law
- Yolanda Pina
- Zhihua Chen
Organizations
- H. Lee Moffitt Cancer Center & Research Institute
- National Cancer Institute
- National Institutes of Health
- United States Department of Defense